Outlook and Analyst Commentary "We see ~6% upside to '26 M+Z ests," Morgan Stanley analysts commented, referring to projections for Mounjaro and Zepbound in 2026
Non-compartmental PK analysis using WinNonlin was performed by using the mean concentrations at each sampling time point to report the C max , T max , the area under the plasma concentration curve from time zero to infinity (AUC 0inf ), T 1/2 , and the mean residence time (MRT)
In the retatrutide trials, the ratio of fat loss to lean loss was favorable compared to caloric restriction alone, where lean mass can represent 25-35% of total weight lost
Additionally, a periodic comparison of the inventory log and medication billing reports should be completed to identify any discrepancies
In that moment, we have not failed the dose the dose has not fully accumulated yet
Body weight and insulin resistance also play important roles